IO Biotech (IOBT) to Release Quarterly Earnings on Monday

IO Biotech (NASDAQ:IOBT) is projected to announce its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, April 3, 2026 at 5:00 PM ET.

IO Biotech Stock Down 7.1%

Shares of NASDAQ:IOBT opened at $0.18 on Monday. The company has a quick ratio of 2.01, a current ratio of 2.01 and a debt-to-equity ratio of 18.29. The business has a fifty day moving average of $0.34 and a two-hundred day moving average of $0.71. The stock has a market cap of $12.71 million, a P/E ratio of -0.13 and a beta of 0.42. IO Biotech has a 52-week low of $0.14 and a 52-week high of $2.79.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on IOBT shares. Morgan Stanley cut shares of IO Biotech from an “equal weight” rating to an “underweight” rating in a research report on Thursday, January 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IO Biotech in a research note on Monday, December 29th. Wall Street Zen upgraded shares of IO Biotech from a “sell” rating to a “hold” rating in a report on Saturday, January 10th. Finally, Piper Sandler cut shares of IO Biotech from an “overweight” rating to a “neutral” rating in a research note on Friday, January 23rd. Three analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, IO Biotech currently has a consensus rating of “Reduce” and an average target price of $6.33.

Institutional Trading of IO Biotech

Hedge funds and other institutional investors have recently modified their holdings of the business. Beacon Pointe Advisors LLC acquired a new position in IO Biotech in the fourth quarter valued at about $308,000. Millennium Management LLC acquired a new stake in shares of IO Biotech during the third quarter valued at about $506,000. Boothbay Fund Management LLC purchased a new stake in shares of IO Biotech in the 3rd quarter valued at approximately $215,000. Marex Group plc purchased a new stake in shares of IO Biotech in the 2nd quarter valued at approximately $63,000. Finally, NewEdge Advisors LLC acquired a new position in shares of IO Biotech in the 2nd quarter worth approximately $34,000. 54.76% of the stock is owned by institutional investors and hedge funds.

About IO Biotech

IO Biotech ApS is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, specializing in the development of novel immuno-oncology therapies. The company’s proprietary platform focuses on activating and sustaining anti-tumor immune responses by targeting the PD-L1 immune checkpoint. IO Biotech’s lead candidate, IO-VAC(R), is a peptide-based cancer vaccine designed to induce durable T-cell responses against PD-L1–expressing tumors.

Since its founding in 2013, IO Biotech has advanced IO-VAC(R) into multiple clinical trials, including Phase II studies in patients with metastatic melanoma.